XML 45 R29.htm IDEA: XBRL DOCUMENT v3.25.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:
RevenueAccounts Receivable, Net
Year Ended December 31,As of December 31,
20252024202320252024
Customer A
****14 %
Customer B
28 %29 %31 %23 %12 %
Customer C
***12 %11 %
*    less than 10%
Schedule of Property, Plant and Equipment
Estimated useful lives for property and equipment are as follows:
Property and EquipmentEstimated Useful Life
Machinery and equipment
5 years
Furniture and fixtures
7 years
Computer hardware and computer software
3 years
Leasehold improvementsLesser of estimated useful life or remaining lease term
Property and equipment, net consist of the following:
As of December 31,
20252024
(in thousands)
Machinery and equipment
$144,069 $124,567 
Leasehold improvements
107,696 103,569 
Computer hardware
41,329 36,497 
Construction in progress
41,252 28,136 
Furniture and fixtures
8,464 7,874 
Computer software
2,006 1,695 
Property and equipment, gross
344,816 302,338 
Less: accumulated depreciation
(198,901)(165,525)
Property and equipment, net
$145,915 $136,813 
Schedule of Disaggregation of Revenue
The following table presents the Company’s revenue disaggregated by revenue source:
Year Ended December 31,
202520242023
(in thousands)
Oncology
$683,595 $542,827 $403,876 
Biopharma and data
210,132 177,579 136,351 
Screening
79,732 5,124 — 
Licensing and other
8,562 13,486 23,721 
Total revenue
$982,021 $739,016 $563,948